8:24AM Biovest conducts meeting with EMA advancing process to seek EU approval for cancer vaccine (BVTI) 0.29 : Biovest International, majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (ABPI), reported milestone achievements advancing BiovaxID, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.